Abstract 148P
Background
To investigate the mean hemoglobin volume (MCV) in predicting the prognosis of residual gastric cancer (RGC).
Methods
A total of 225 RGC patients who underwent R0 resection in three hospitals in China from January 2003 to June 2015 were enrolled. The 3-year survival time were compared. Two-step regression was performed to analyze the effect of MCV on prognosis in RGC patients.
Results
A total of 208 patients were included in the final analysis, including 135 in Group L (MCV < 100 fl) and 73 in Group N (100 ≤ MCV < 120 fl). In different hospitals, there were different RGC occurrence times and initial gastric surgery intervals and different initial surgical reconstruction methods, the MCV value was not significantly correlated with hemoglobin content (R2=0.397). Comparing the 3 years overall survival time (OS) and disease-free survival time (DFS) with Group L, Group N patients were all better (P < 0.001). The stratified analysis showed that for stage III, with no anemia or mild anemia and chemotherapy, Group N patients had significantly better OS and DFS than the Group L patients (P < 0.05). Two-step multivariate analysis showed that MCV was an independent factor for the OS and DFS, and both the OS and DFS decreased as the MCV decreased (P<0.001).
Conclusions
MCV showed significant heterogeneity in patients with different RGC. Patients with low MCV have a significantly poor prognosis, and the MCV can therefore be a simple and effective indicator for assessing the prognosis of patients with RGC.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Scientific and Technological Innovation Joint Capital Projects of Fujian Province.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
325P - Clinical characteristics and outcomes of cancer patients with COVID-19 infection: A retrospective study in a single center in the Philippines
Presenter: Frances Victoria Que
Session: e-Poster Display Session
326P - Management of diffuse large B cell lymphomas in the COVID-19 era
Presenter: David Ng
Session: e-Poster Display Session
327P - COVID-19 in patients with oncohematologic diseases in Kazakhstan
Presenter: Zaure Dushimova
Session: e-Poster Display Session
328P - Impact of COVID-19 pandemic on 30 days colorectal cancer patients mortality undergoing emergency operation
Presenter: Ida Bagus Budhi
Session: e-Poster Display Session
329P - Radiotherapy palliative and COVID-19: Experience of radiotherapy oncology department of Cancer Center Tlemcen, Algeria
Presenter: Asma Mous
Session: e-Poster Display Session
330P - COVID and cancer: Choosing between hammer and anvil
Presenter: Ullas Batra
Session: e-Poster Display Session
331P - The clock stopped with COVID-19 but continued ticking for cancer patients
Presenter: Sasi Shanmugam Senga
Session: e-Poster Display Session
336P - Efficacy of methylcobalamin administered intravenously for chemotherapy-induced peripheral neuropathy (CIPN): A prospective crossover study
Presenter: Jun Chen
Session: e-Poster Display Session
337P - A prospective study about the quality of life and chemotherapy-induced peripheral neuropathy
Presenter: Wala Ben Kridis
Session: e-Poster Display Session
338P - Vitamin E in the treatment of chemotherapy and radiation-induced mucositis: A meta-analysis of randomized controlled trials
Presenter: Michelle Joane Alcantara
Session: e-Poster Display Session